Literature DB >> 23707524

New advances of DNA methylation in liver fibrosis, with special emphasis on the crosstalk between microRNAs and DNA methylation machinery.

Er-Bao Bian1, Bing Zhao, Cheng Huang, Hua Wang, Xiao-Ming Meng, Bao-Ming Wu, Tao-Tao Ma, Lei Zhang, Xiong-Wen Lv, Jun Li.   

Abstract

Epigenetics refers to the study of heritable changes in the pattern of gene expression that is controlled by a mechanism specifically not due to changes the primary DNA sequence. Well-known epigenetic mechanisms include DNA methylation, post-translational histone modifications and RNA-based mechanisms including those controlled by small non-coding RNAs (miRNAs). Recent studies have shown that epigenetic modifications orchestrate the hepatic stellate cell (HSC) activation and liver fibrosis. In this review we focus on the aberrant methylation of CpG island promoters of select genes is the prominent epigenetic mechanism to effectively silence gene transcription facilitating HSC activation and liver fibrosis. Furthermore, we also discuss epigenetic dysregulation of tumor-suppressor miRNA genes by promoter DNA methylation and the interaction of DNA methylation with miRNAs involved in the regulation of HSC activation and liver fibrosis. Recent advances in epigenetics alterations in the pathogenesis of liver fibrosis and their possible use as new therapeutic targets and biomarkers.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23707524     DOI: 10.1016/j.cellsig.2013.05.017

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  PNPO Deficiency and Cirrhosis: Expanding the Clinical Phenotype?

Authors:  D Coman; P Lewindon; P Clayton; K Riney
Journal:  JIMD Rep       Date:  2015-06-25

2.  Characterization of body composition and liver epigenetic markers during periods of negative energy balance and subsequent compensatory growth in postpubertal beef bulls.

Authors:  Felipe H Moura; Mozart A Fonseca; Arturo Macias-Franco; Evandro C Archilia; Isadora M Batalha; Camilo A Pena-Bello; Aghata E M Silva; Gabriel M Moreira; Luis F Schütz; Aaron B Norris
Journal:  J Anim Sci       Date:  2022-03-01       Impact factor: 3.338

Review 3.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

4.  The interaction between microRNA-152 and DNA methyltransferase-1 as an epigenetic prognostic biomarker in HCV-induced liver cirrhosis and HCC patients.

Authors:  Rady E El-Araby; Mahmoud A Khalifa; Mona M Zoheiry; Manal Y Zahran; Mohamed I Rady; Raafat A Ibrahim; Mohamed D El-Talkawy; Faiza M Essawy
Journal:  Cancer Gene Ther       Date:  2019-07-18       Impact factor: 5.854

5.  Pathological mechanisms and therapeutic outlooks for arthrofibrosis.

Authors:  Kayley M Usher; Sipin Zhu; Georgios Mavropalias; John A Carrino; Jinmin Zhao; Jiake Xu
Journal:  Bone Res       Date:  2019-03-26       Impact factor: 13.567

6.  Integrated analysis of differentially expressed genes, differentially methylated genes, and natural compounds in hepatitis C virus-induced cirrhosis.

Authors:  Junxiong Cheng; Zhiwei Chen; Guoqing Zuo; Wenfu Cao
Journal:  J Int Med Res       Date:  2022-01       Impact factor: 1.671

7.  Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease.

Authors:  Qing-Feng Sun; Liang-Jie Tang; Ming-Jie Wang; Pei-Wu Zhu; Yang-Yang Li; Hong-Lei Ma; Ou-Yang Huang; Liang Hong; Gang Li; Christopher D Byrne; Giovanni Targher; Wen-Yue Liu; Yan Lu; Ji-Guang Ding; Ming-Hua Zheng
Journal:  Front Med (Lausanne)       Date:  2022-03-31

8.  Epigenetic differences of chronic hepatitis B in different TCM syndromes: Protocol for a case-control, non-interventional, observational clinical study.

Authors:  Li Ma; Xiuli Zheng; Yu Yang; Jian Wang; Youli Xu; Baojia Wang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.